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Abstract 
Background: Keeping substance use disorder patients actively engaged in treatment is a challenge. Horse‑assisted 
therapy (HAT) is increasingly used as a complementary therapy, with claimed motivational and other benefits to 
physical and psychological health. This naturalistic study aimed to assess HAT’s impact on the duration and comple‑
tion of treatment for young substance users at Oslo University Hospital.
Methods: Discharge and other data were derived from the Youth Addiction Treatment Evaluation Project (YATEP) 
database for patients (n = 108) admitted during an 18‑month period. An intention‑to‑treat design, and univariate 
and multivariate analyses were used to compare those receiving treatment as usual (n = 43) with those who received 
treatment as usual plus HAT (n = 65).
Results: Despite a lack of randomization, the baseline characteristics of the two groups were similar. However, more 
HAT participants completed treatment (56.9 vs 14 %, p < 0.001), remained in treatment for longer (mean 141 vs 
70 days, p < 0.001) and had a significantly higher chance of completing their treatment than those not given the HAT 
program. Excluding time in treatment, and after controlling for the potentially confounding influence of age, sex, edu‑
cation, number and severity of substances used, psychological distress and number of temporary exits, the adjusted 
odds ratio for treatment completion was 8.4 in the HAT group compared with those not participating in HAT (95 % CI 
2.7–26.4, p < 0.001).
Conclusion: The study found a statistically significant association between HAT participation and time in treatment, 
and between HAT participation and completion of treatment. This association does not infer causality. However, it 
adds supporting evidence for the development of an innovative therapy, and warrants investment in further research 
in relation to its inclusion in substance use disorder treatment.
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Background
Retention in treatment improves the prognosis for sub-
stance use disorder patients [1–3]. Early dropouts are 
reported to have the same outcome as untreated patients 
[3]. There have been four major reviews of dropout from 
addiction and substance use disorder treatment [3–6], 
and these involve more than 500 studies undertaken over 
almost 40 years. They report that despite wide diversity in 
treatment methods [7], patient failure to complete ther-
apy (usually referred to as dropout) often exceeds 50 %. 
Completion of treatment is associated with successful 
outcomes [3, 4, 8, 9]. The optimal duration of treatment 
is debatable and may depend upon the treatment method 
[10], but 90 days is often identified as the minimum time 
period for effective treatment [2, 3, 11–13]. In addition, 
many substance use patients exit treatment for various 
reasons and then re-enter treatment after varying periods 
of absence [3, 4, 13]. There is a continuous struggle to find 
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treatment modalities that motivate patients to remain for 
sufficient time to enable beneficial change in morbid-
ity [10]. Treatment factors such as method, staff–patient 
alliance and interaction, and satisfaction, although less 
frequently studied, have been found to be among the best 
predictors of outcome [6]. Reported studies of alterna-
tive or complementary treatment methods are rare [14], 
including those for substance use disorders.
Horse (or equine)-assisted/facilitated therapy is an 
innovative complementary approach to psychotherapy 
that actively involves horses or other equines in the ther-
apeutic process. Challenges in this rapidly developing 
field of experimental therapy include increasing the pro-
vision of a high-cost therapy, which is often of unknown 
quality, to vulnerable population groups with little sub-
stantiating evidence of associated benefits [15].
Since the 1990s, there has been a dramatic increase 
in the number of equine programs that claim to pro-
vide psychotherapy and/or education and development. 
However, equine-assisted/facilitated psychotherapy is 
still very much in an evolutionary phase, lacking a gener-
ally accepted theoretical framework. There is a variety of 
emerging schools of thought, approaches and terminol-
ogy [16–18]. The term horse-assisted therapy (HAT) is 
used in this paper.
A review of the literature and media relating to psycho-
therapy involving horses has revealed a growing number 
of studies and “opinion-based” material in the psycho-
social area with a variety of factors at play, including 
motivation. These include claims that the size, strength, 
warmth, body language and herd behavior of horses can 
be used with therapeutic benefit when working with cli-
ents who are mistrusting, depressed and anxious [16, 
18–21], or who lack the boundary setting or other skills 
needed to deal with everyday living [22, 23] or who have 
issues related to self-esteem, self-efficacy or resilience [24, 
25]. In addition, there are claims that the horse “mirrors” 
the patient and provides immediate, honest feedback, 
untainted by the usual human and social constraints [16, 
21], and that the horse can promote trust in vulnerable 
clients, particularly those with traumatic backgrounds 
[20, 26]. Dell and colleagues refer to the importance of 
the horse’s consistency, and nonverbal and nonjudgmen-
tal relationship with Inuit youth undergoing substance 
abuse treatment [27]. In general, the horse is reported to 
be a motivational force for treatment [28–30].
However, the studies are usually small and rarely docu-
mented in an adequate or systematic format. There have 
been two published systematic reviews of peer-reviewed 
literature of psychotherapeutic programs involving 
horses [15, 31]. The first reviewed material in 16 data-
bases, identifying 103 studies, of which 14 met the selec-
tion criteria. Only two of these were rated as having 
evidence of (moderate) effectiveness [31]. The second, 
in mid-2014, reviewed 14 studies identified from a more 
restricted search and found that all 14 were compro-
mised by threats to validity. The authors concluded that 
psychotherapy involving equines should not be marketed 
but that research should continue with improved meth-
odology [15]. Since then, findings from a randomized 
controlled study have been published. The study found 
that long-term psychiatric patients at risk of violence 
responded positively to a program of equine-assisted 
psychotherapy [32].
Many horse centers offer therapy for substance use, or 
addiction programs [33], but few studies are reported. 
We found nine specific HAT and substance use disorder-
related papers or theses, only one of which was in a peer-
reviewed journal [27]. None of them met the inclusion 
criteria for the two systematic reviews.
Most reported studies of HAT, including those relating 
to substance use and addiction, conclude with a recom-
mendation for further research. However, few HAT pro-
grams have the resources, patient numbers, diagnostic 
homogeneity, or the research capacity and skills required.
In 2010, Oslo University Hospital’s Department of 
Addiction Treatment—Youth provided a unique research 
opportunity to study HAT. It had approximately 100 new 
patients per year with a primary diagnosis of substance 
use and/or addiction. In addition, it had 37 years’ expe-
rience of HAT in a residential psychiatric setting [22]. 
Since 2010, the hospital’s resident herd of five specially 
selected and trained horses has worked exclusively with 
the department’s young patients in a structured, sub-
stance use disorder-relevant program of HAT.
As far as we are aware, this is the first peer-reviewed 
quantitative study of the inclusion of HAT in a substance 
use disorder treatment program. Our objective was to 
assess whether HAT patients remained in treatment 
longer and were more likely to complete their agreed 
program of treatment. We hypothesized that HAT par-
ticipation was associated with both longer time in treat-
ment and completion of treatment.
Methods
The study covered an 18-month treatment period from 
January 1, 2011. It was part of a larger, ongoing, mixed-
methods project to investigate the impact of HAT on 
substance use disorder treatment outcomes.
Patient participation was voluntary. All necessary 
patient consent and data inspection authority approvals 
were obtained as part of the Youth Addiction Treatment 
Evaluation Project (YATEP). The study was reviewed 
and approved by the Norwegian Regional Committee for 
Medical Research Ethics, and performed according to 
their guidelines and the Helsinki Declaration.
Page 4 of 12Kern‑Godal et al. Addict Sci Clin Pract  (2015) 10:21 
Patients
The study sample comprised inpatients and day patients 
admitted between January 1, 2011 and June 30, 2012 to 
the Department of Addiction Treatment—Youth at Oslo 
University Hospital. The department treats men and 
women aged 16–26  years (but patients up to 35  years 
of age may be accepted) who have a primary diagnosis 
of mental and behavioral disorders due to psychoactive 
substance use (ICD 10). One hundred eleven patients 
entered treatment during the 18-month period. Three 
patients were discharged to other institutions for ongoing 
treatment, leaving 108 patients in the study.
Study design
At entry to treatment, all participating patients who had 
provided written informed consent were registered in the 
YATEP database. Recording usually started in the first 
week. The database comprises basic patient information, 
psychological tests, discharge status, and HAT participa-
tion data. Additional patient demographic, morbidity and 
treatment information, plus the dates of any temporary 
exit from treatment, can be drawn from the hospital’s 
electronic patient journal when required and matched 
anonymously to the YATEP database records. All indi-
viduals were followed from treatment entry to discharge.
Measures
The study outcomes were: (1) completion of treatment 
(primary outcome), (2) time in treatment (measured 
using number of treatment days), and (3) completion of 
90 days of treatment or more (included because it is often 
identified as a critical period for effective treatment [2, 3, 
11–13]).
Discharge status was categorized as (1) treatment com-
pleted, or (2) dropout. Treatment completed was defined 
as staying in treatment for the duration of the recom-
mended treatment plan. This was determined by exam-
ining the YATEP discharge report and the clinician’s 
journal record. Those who left the program but returned 
within a 30  day period to continue with the remainder 
of the treatment course were considered to have com-
pleted treatment. Leaving the program but returning 
within a 30 day period was termed “temporary exit.” The 
number of days of temporary exit was excluded from the 
total treatment days at discharge. Dropout was defined as 
patient initiated treatment termination, or expulsion for 
rule violation prior to completing the agreed treatment 
period.
Psychological distress was measured using the Hop-
kins Symptom Check List 25 (HSCL-25), which is one 
of the assessment items in the YATEP. It consists of 25 
questions that map respondents’ anxiety and depres-
sion [34]. It is scored on a scale from 1 (not bothered) to 
4 (extremely bothered). The form is frequently used in 
Norwegian research projects with 1.75 as the risk cutoff 
in normal Norwegian populations [35]. In the analysis for 
this study, HSCL-25 was used as an indicator of psycho-
logical distress.
Severity of substances used was categorized as more 
severe [heroin, amphetamine, benzodiazepine, gamma 
hydroxybutyrate (or GHB) and cocaine] or less severe 
(cannabis and alcohol).
Treatment as usual (TAU)
The treatment site is part of the specialist health care 
system in Norway. Patients are referred by general prac-
titioners and specialists or from other hospital depart-
ments. They must have a primary diagnosis of mental and 
behavioral disorders due to psychoactive substance use 
(ICD 10). The social services authority has oversight of 
this process. The treatment is a person-centered program 
which comprises individual and group therapy based on 
a biopsychosocial model with emphasis on mentaliza-
tion-based theory and practice [36]. An individual treat-
ment plan, which includes treatment goals, is prepared 
in cooperation with each patient. Medical treatment is 
offered, as well as assistance/counselling for accommo-
dation, education, employment, living, adjustment and 
support. Psychological treatment is tailored to the indi-
vidual’s specific problems and treatment goals. The likely 
duration of treatment is decided with the patient as part 
of the treatment plan, in accordance with their needs. It 
can include movement between units, such as from inpa-
tient to day patient. In the day unit, as patients become 
more established in school, work or a domestic situation, 
the therapist gradually reduces contact until discharge.
The HAT intervention
HAT is an integral part of the department’s program of 
addiction treatment [37]. It comprises 12× 90-min ses-
sions of body-orientated psychotherapy with horses. The 
animals have been selected and trained for this work to 
be strong, secure, responsive and interactive. Patients 
and staff are insured against injury by the hospital. Seri-
ous incidents and injuries must be recorded.
All patients are eligible to participate in HAT, but must 
be referred by their treating clinician. The referral can be 
requested by the patient or suggested by the clinician. 
A final decision on suitability and the treatment objec-
tives of the individual’s HAT participation (for exam-
ple, to strengthen boundary setting, or reduce anxiety, 
depression or aggression, etc.) are agreed at a prepara-
tory meeting between the HAT therapist, the patient and 
the clinician. Patients have the opportunity to meet the 
horses and become involved in care activities (such as 
feeding) from their first day in treatment. They normally 
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start the HAT program within 2–3 weeks. HAT thera-
pists become part of the patient’s clinical team, with full 
access to the patient’s clinical record. Patients are encour-
aged to attend and participate fully but can choose not 
to undertake an activity, such as mounted work. Specific 
activities, level of participation and response at each 
HAT session are recorded by the HAT therapists in the 
patient’s electronic hospital journal.
The sessions are planned and provided by two quali-
fied therapists who are also Norwegian Level 1 Riding 
Instructors. The program design is structured for small 
groups (maximum four participants per session), but 
includes provision for individual work on specific needs 
if required. It involves a three-way interactive (positive 
triangulated) process in which the patient works in emo-
tional safety with the horse on activities selected with 
his/her therapist to address agreed goals. During ses-
sions, the horse will respond naturally to environmental 
factors (for example, the proximity of other horses, or a 
sudden loud noise). Similarly, it will react to the physical 
and emotional state of the patient (for example, a request 
lacking focus or clarity is unlikely to produce the desired 
movement from the horse, and an aggressive request may 
be met with resistance). The therapist, in leading the pro-
cess, can both read and influence the horse, and provide 
reflective feedback to the patient on the relationship, 
reactions and responses between the horse and patient.
Activities can involve any combination of herd behav-
ior observation, stable duties, and ground, mounted 
and/or driving work with the horses. Observation of the 
herd can promote discussion of social interaction and 
relationships and stable duties promote responsibility, 
routine and reliability. Groundwork is used to address 
issues relating to boundaries/contact, anxiety/trust, 
communication/connection, mastery (of new skills, the 
horse and self ), body awareness and focus. Mounted 
work addresses posture, balance/centering, coordination, 
rhythm/regulation, mastering of anxiety and focus. Car-
riage driving can be used to promote forward thinking 
and outlook, and, with other passengers, it can engender 
a sense of empowerment, group responsibility and care. 
These activities involve good healthy exercise, having fun, 
and learning new skills. However, while physical exercise, 
fun and skill acquisition are important, the prime pur-
pose of this program is therapy and contribution to suc-
cessful treatment.
The focus of the first four sessions is on getting to know 
about horses, herd behavior, basic handling and safety. 
The following eight sessions are tailored to meet the indi-
vidual’s therapy objectives using a range of group and 
individual ground-based, mounted or driving exercises as 
outlined in the stable manual (unpublished).
The HAT program has been developed at Oslo 
University Hospital over time, largely by Lysell [22], 
a qualified and experienced body-oriented psycho-
therapist. It also draws on theoretical and practice 
material from a number of relevant equine-assisted 
therapy schools [16, 20, 38–42]. It uses many of the 
usual equine-assisted/facilitated therapy exercises 
but places stronger emphasis on those relevant to 
substance use disorders, such as boundary setting, 
development of trust and control of emotional affect. 
It differs from most other horse therapy programs 
in two aspects. First, the patients have responsibil-
ity for the horses after hours, giving greater empha-
sis on care, routine, reliability and responsibility (all 
relevant to substance use recovery). Second, after the 
four introductory sessions, the HAT program does not 
follow a sequenced routine. Rather, specific activities 
and therapeutic processing are targeted at individual 
patient needs and are sequenced at appropriate points 
throughout the patient’s HAT program.
HAT treatment outcome is not assessed per se. It is 
included as part of the patient’s overall treatment out-
come assessment, as measured by change in the YATEP 
psychological instruments and, in particular, by whether 
individuals complete their agreed substance use treat-
ment program.
Statistical analysis
In this naturalistic, intention-to-treat study, univari-
ate and multivariate analyses were used to assess the 
relationship between treatment completion and HAT 
plus a range of patient factors (gender, age, education, 
number and severity of substances used, psychological 
distress and number of temporary exits). We included 
time in treatment as an additional outcome measure. It 
is assessed using univariate analysis of both the mean 
(113 days) and the reported critical minimum period for 
effective treatment (90 days). However, we excluded time 
in treatment from the logistic regression because of the 
obvious relationship between longer time in treatment 
and treatment completion.
Pearson Chi squared and independent-samples t test 
were used to test the relationship between discharge 
status and HAT. Odds ratio (OR) was used to test the 
strength of the relationship. Potential confounding vari-
ables relating to the patient (age, sex, education, num-
ber and severity of substances used, and psychological 
distress), time in treatment (mean time and temporary 
exits) and HAT participation were controlled for using 
logistic regression analysis. Linear and other interactive 
associations were checked. SPSS Version 21 (IBM Corp., 
Armonk, NY, USA) was used.
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Results
Study participants’ characteristics
The study involved 108 individuals: 78 males and 30 
females (27.8  %). At the time of entry to treatment, 14 
(13.0  %) were aged less than 20  years, 74 (68.5  %) were 
20–26  years and 20 (18.5  %) were aged 27  years or 
older (Table  1). The mean age (results not shown) was 
23.1 years (range 17–33 years, SD = 3.4). Females (mean 
22.9 years, SD = 3.5) were slightly, but not significantly, 
younger than males. None of the patients were under 
legal mandate to remain in treatment.
In the 6  months prior to intake, 32.4  % of the 108 
patients had used a single drug, 28.7  % had used two 
drugs and 39.9 % had used three or more drugs. Canna-
bis was the most commonly used primary drug (38.9 %), 
followed by alcohol (18.5  %), amphetamine  +  cocaine 
(15.8  %), heroin (15.7  %) and other drugs (11.1  %). The 
average age of first use of the primary drug was 17 years, 
(results not shown) with 52.8  % of all patients being 
15  years or younger when they first used their primary 
drug (Table 1).
At referral, all patients had a primary diagnosis of 
mental and behavioral disorders due to psychoac-
tive substance use (ICD 10). Fifty-eight (53.7  %) of the 
patients were reported to have no psychiatric comorbid 
condition, 34 (31.5 %) had one, and 16 (14.8 %) had two 
or more. The most common of the comorbid conditions 
(results not shown) were behavioral disorders (36.2  %), 
followed by neurotic/stress (including post-traumatic 
stress disorder) disorders (34.8  %), mood disorders 
(20.3  %) and other disorders (8.7  %). Approximately 
1  week after entry, 89 (82.4  %) patients’ first Hopkins 
Symptom Check List 25 (HSCL-25) scores were equal 
to or above the psychosocial risk cutoff. Sixteen patients 
(14.8  %) were prescribed substitution medicine (15 
buprenorphine, 1 methadone) during all or part of their 
treatment (Table 1).
HAT participation
Forty-three patients (39.8 %) received treatment as usual 
(non-HAT group) and 65 (60.2 %) had treatment as usual 
plus HAT (HAT intervention group). The intervention 
was well tolerated with no reported adverse treatment 
effect or injury arising from HAT. None of the patients 
were withdrawn from HAT for clinical reasons.
Although this was a naturalistic study, there were no 
major differences in baseline characteristics between the 
HAT group and the non-HAT group. However, signifi-
cantly more HAT participants were aged 27 years or more 
(24.6 vs 9.3 %, p = 0.03) and their average age was slightly 
older than non-HAT participants (mean 23.7  years, 
SD = 3.4 vs mean 22.1 years, SD = 3.2, p < 0.02) (results 
not shown). They were also more likely than non-HAT 
participants to have one or more temporary exits from 
treatment (49.2 vs 25.6 %, p = 0.05) (Table 1).
Thirty-seven (56.9  %) of HAT participants completed 
their treatment compared with only six (14.0 %) of non-
HAT participants, p < 0.001 (Table 1).
Time in treatment
Days in treatment ranged from 1 to 555, (mean 113, 
SD  =  92.7). Twenty-six (24.0  %) of the 108 patients 
remained in treatment for less than 30 days, 49 (21.3 %) 
for 30–89  days and 59 (54.6  %) for 90  days or more 
(results not shown). Forty-eight (44.4  %) remained in 
treatment for the mean 113 days or more, and 33 (76.7 %) 
of those completed treatment (Table 2).
HAT participants remained in treatment for a signifi-
cantly longer period (p < 0.001) than those who did not 
participate in HAT (mean 141 days, SD = 93.6, vs mean 
70 days, SD = 73.8). They were almost four times more 
likely to remain in treatment for 90 days or more (OR 3.9 
CI 1.7–8.8, p = 0.001) (results not shown).
Treatment discharge status
At discharge, 43 (39.8 %) of the 108 patients in the study 
had completed treatment and 65 (60.3  %) had dropped 
out. Treatment completion was significantly associ-
ated with only HAT participation [χ2 (1,108)  =  19.9, 
p < 0.001] and length of time in treatment {for both mean 
days in treatment [χ2 (1,108) = 30.2, p < 0.001] and the 
critical 90  days period [χ2 (1,108)  =  32.8, p  <  0.001] 
(Table 2)}.
Prediction of treatment completion
Apart from the length of time in treatment, HAT par-
ticipation was the only significant univariate predictor 
of treatment completion (OR 8.2, CI 3.0–22.0, p < 0.001) 
(results not shown). Excluding time in treatment, and 
after controlling for the potentially confounding influ-
ence of age, sex, education, number and severity of 
substances used, psychological distress and temporary 
exits, the adjusted odds ratio for HAT participants com-
pleting treatment was 8.4 (95 % CI 2.7–26.4, p < 0.001), 
(Table 3).
Discussion
This study found a statistically significant association 
between HAT participation and longer time in treatment, 
and between HAT participation and completion of treat-
ment. Although not direct measures of substance use, 
both duration and completion of treatment are reported 
in previous studies to be predictors of positive treatment 
outcome for substance use disorders [3, 4, 8, 9].
Length of time in treatment was the strongest pre-
dictor of treatment completion. This is consistent with 
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previously reported studies [1, 3, 13], but it may hide the 
influence of other patient or treatment variables [4, 10], 
such as HAT in our study. The optimal duration of treat-
ment is debatable and may depend upon the individual 
needs of the patient and the type of treatment method 
[10]. However, 90 days is often identified as the minimum 
period for effective treatment [2, 3, 11–13].
HAT participants were significantly more likely 
than non-HAT participants to remain in treatment 
for 90  days or more and to complete their treatment. 
Table 1 Comparison of patient characteristics: treatment as usual (not-horse assisted therapy) with intervention group 
(treatment as usual plus horse assisted therapy)
a Not horse assisted therapy/horse assisted therapy
b Gamma hydroxybutyrate (C4H8O3)
c Hopkins Symptom Checklist‑25
d Opioid pharmacotherapy
Variable Item Not-HATa HATa Total % Chi square
N = 43 N = 65 N = 108 100
Discharge status Dropped out 37 (86.0) 28 (43.1) 65 60.2 19.94, p < 0.001
Completed 6 (14.0) 37 (56.9) 43 39.8
Days in treatment
 Mean <113 days 32 (74.4) 28 (43.1) 57 55.6 10.30, p = 0.001
113+ days 11 (25.6) 37 (56.9) 51 44.4
 Critical period <90 days 28 (65.1) 21 (32.3) 49 45.4 11.24, p = 0.001
90+ days 15 (34.9) 44 (67.7) 59 54.6
Gender Female 8 (18.6) 22 (33.8) 30 27.8 2.10, p = 0.083
Male 35 (81.4) 43 (66.2) 78 72.2
Age <20 years 9 (20.9) 5 (7.7) 14 13 6.80, p = 0.034
20–26 years 30 (69.8) 44 (67.7) 74 68.5
27+ years 4 (9.3) 16 (24.6) 20 18.5
Years of schooling <10 years 7 (16.3) 11 (16.9) 18 16.7 2.42, p = 0.298
10–12 years 31 (72.1) 39 (60.0) 70 64.8
13+ years 5 (11.6) 15 (23.1) 20 18.5
Primary substance Cannabis 20 (46.5) 22 (33.8) 42 38.9 6.31, p = 0.389
Alchol 6 (14.0) 14 (21.5) 20 18.5
Heroin 6 (14.0) 11 (16.9) 17 15.7
Amphetamine 4 (9.3) 11 (16.9) 15 13.9
Benzodiazepine 3 (7.0) 5 (7.7) 8 7.4
GHBb 2 (4.7) 2 (3.1) 4 3.7
Cocaine 2 (4.7) 0 (0.0) 2 1.9
No. of substances 1 substances 12 (27.9) 23 (35.4) 35 32.4 0.82, p = 0.662
2 substances 14 (32.6) 17 (26.2) 31 28.7
3 substances 17 (39.5) 25 (38.5) 42 38.9
Age of first use <16 years 25 (58.1) 32 (49.2) 57 52.8 0.82, p = 0.364
16+ years 18 (41.9) 33 (50.8) 51 47.2
HSCL‑25c <1.75 9 (20.9) 10 (15.4) 19 17.6 0.55, p = 0.459
1.75+ 34 (79.1) 55 (84.6) 89 82.4
Subsitution medicined No 38 (88.4) 54 (83.1) 92 85.2 0.58, p = 0.450
Yes 5 (11.6) 11 (16.9) 16 14.8
Psych. co‑morbidity (at entry) None diagnosed 21 (48.8) 37 (56.9) 58 53.7 1.10, p = 0.580
1 diagnosed 16 (37.2) 18 (27.7) 34 31.5
2+ diagnosed 6 (14.0) 10 (15.4) 16 14.8
Temporary exit No exit 32 (74.4) 33 (50.8) 65 60.2 6.10, p = 0.05
1 re‑entry 6 (14.0) 18 (27.7) 24 22.3
2+ re‑entries 5 (11.6) 14 (21.5) 19 17.6
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However, they were also more likely to have had a 
temporary exit. This may seem anomalous with some 
regarding any unscheduled exit as negative. However, 
return to complete treatment is encouraged and it is 
possible that attachment to the horses may have made 
the decision to return a little easier for some. Further 
controlled studies are needed to clarify the causal 
relationship between HAT and temporary exit, duration 
and completion of treatment.
A major challenge in addiction treatment is to iden-
tify what treatment modality or other factors motivate 
patients to stay in treatment [6, 10, 43, 44]. Treatment 
factors (method, setting, duration, staff/patient ratio) 
and treatment process factors (motivation, alliance, 
Table 2 Comparison of discharge status: dropout or completed by patient characteristics
a Gamma hydroxybutyrate (C4H8O3)
b Opioid pharmacotherapy
c Hopkins Symptom Checklist‑25
Variable Item Dropout Completed Total % Chi square
N = 65 N = 43 N = 108 100
Participation in HAT No 37 (56.9) 6 (14.0) 43 39.8 19.94, p < 0.001
Yes 28 (43.1) 37 (86.0) 65 60.2
Days in treatment
 Mean <113 days 50 (76.9) 10 (23.3) 60 55.6 30.18, p < 0.001
113+ days 15 (23.1) 33 (76.7) 48 44.4
 Critical period <90 days 44 (67.7) 5 (11.6) 49 45.4 32.82, p < 0.001
90+ days 21 (32.3) 38 (88.4) 59 54.6
Gender Female 16 (24.6) 14 (32.6) 30 27.8 0.81, p = 0.367
Male 49 (75.4) 29 (67.4) 78 72.2
Age <20 years 12 (18.5) 2 (4.7) 14 13 4.81, p = 0.090
20–26 years 43 (66.2) 31 (72.3) 74 68.5
27+ years 10 (15.4) 10 (23.3) 20 18.5
Years of schooling <10 years 13 (20.0) 5 (11.6) 18 16.7 1.96, p = 0.376
10–12 years 42 (64.6) 28 (65.1) 70 64.8
13+ years 10 (15.4) 10 (23.3) 20 18.5
Primary substance Cannabis 23 (35.4) 19 (44.2) 42 38.9 4.75, p = 0.577
Alchol 14 (21.5) 6 (14.0) 20 18.5
Heroin 12 (18.5) 5 (11.6) 17 15.7
Amphetamine 7 (10.8) 8 (18.6) 15 13.9
Benzodiazepine 5 (7.7) 3 (7.0) 8 7.4
GHBa 2 (3.1) 2 (4.7) 4 3.7
Cocaine 2 (3.1) 0 (0.0) 2 1.9
No. of substances 1 substances 20 (30.8) 15 (34.9) 35 32.4 0.15, p = 0.292
2 substances 16 (24.6) 15 (34.9) 31 28.7
3 substances 29 (44.6) 13 (30.2) 42 38.9
Age of first use <16 years 35 (53.8) 22 (51.2) 57 52.8 0.08, p = 0.785
16+ years 30 (46.2) 21 (48.8) 51 47.2
Substitution medicineb No 55 (84.6) 37 (86.0) 92 85.2 0.42, p = 0.840
Yes 10 (15.4) 6 (14.0) 16 14.8
HSCL‑25c <1.75 12 (18.5) 7 (16.3) 19 17.6 0.09, p = 0.771
1.75+ 53 (81.5) 36 (83.7) 89 82.4
Psych co‑morbidity (at entry) None diagnosed 32 (49.2) 26 (60.5) 58 53.7 2.25, p = 0.325
1 diagnosed 24 (36.9) 10 (23.3) 34 31.5
2+ diagnosed 9 (13.8) 7 (16.3) 16 14.8
Temporary exit No exit 42 (64.6) 23 (53.5) 65 60.2 1.87, p = 0.393
1 re‑entry 14 (21.5) 10 (23.3) 24 22.3
2+ re‑entries 9 (13.8) 10 (23.3) 19 17.6
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satisfaction, and interaction) are amongst the best predic-
tors of treatment outcome [6, 44]. Furthermore, Simpson 
and colleagues suggest that use of therapeutic process 
and environmental influences as treatment enhancement 
may improve substance use outcomes [45]. HAT, in this 
study, is an innovative adjunct-treatment factor.
From the substance use and the HAT literature, we 
identified a number of possible explanations for why 
HAT participants may remain in and complete treat-
ment. These include therapeutic alliance, the envi-
ronment, physical activity, staff influence, individual 
attention and comorbidity.
Relational factors and therapeutic alliance can pre-
dict retention in treatment [1] and treatment outcome 
[44]. Premature termination of treatment and poor 
therapeutic alliance have been consistently reported in 
the scientific literature as predictors of negative treat-
ment outcome [2–4, 6, 46]. Many HAT studies refer to 
the human–horse relationship as a positive motivat-
ing factor in therapy [16, 18, 20, 31, 47]. Burgon argues 
that building rapport with the horse increases comfort 
in the therapeutic relationship and leads to positive 
change and learning [25]. This may well be true, but we 
were unable to find substantiating quantitative studies 
of HAT and therapeutic alliance. It warrants further 
study.
As other experienced therapists report, many young 
patients respond better to the therapist in an active, less 
verbal environment than they do sitting in the more for-
mal environment of a therapist’s office [20, 43, 46, 47, 53]. 
Inclusion of an adjunct activity, such as gardening, music 
or art therapy, is also reported to be associated with suc-
cessful treatment completion, as Decker et  al. found in 
their pilot study of novel treatments [43].
A pleasant environment, physical activity and hobbies 
can have a beneficial impact in addiction and related psy-
chological treatment [48–52]. HAT is a body-oriented 
psychotherapy with a range of physical activities, most 
of which occur outdoors in a pleasant, natural and quiet 
environment where therapeutic activities can be adapted 
to the seasons. Staff can also influence retention [2, 4, 
5]. The HAT team works in a relaxed, non-judgmental 
atmosphere with patients, to explore and work on their 
issues.
Patients “are likely to continue in treatment longer 
… with individual attention and when seen in smaller 
groups in friendly comfortable environments” (Stark, 
1992, p. 93) [3]. HAT sessions are conducted in small 
groups of not more than four patients with four staff, 
or in individual patient–therapist sessions. Patients can 
choose to work with their preferred horse, and most 
have a favorite. Other substance use studies have found 
Table 3 Logistic regression predicting likelihood of completing treatment: a multivatiate model of all variables listed
a Less severe (cannabis and alchol) more severe (heroin, amphetamine, benzodiazepine, Gamma hydroxybutyrate, cocaine)
b Hopkins Symptom Checklist
Variable Item Total % p value Odds ratio Confid. lower Interval upper
Participation in HAT No (0) 43 39.8
Yes (1) 65 60.2 <0.01 8.42 2.7 26.4
Gender Female (0) 30 27.8
Male (1) 78 72.2 0.84 0.90 0.3 2.6
Age <20 years (0) 14 13 0.25
20–26 years (1) 74 68.5 0.11 4.37 0.7 26.0
27+ years (2) 20 18.5 0.13 4.78 0.6 36.2
Years of schooling <10 years (0) 18 16.7 0.41
10–12 years (1) 70 64.8 0.20 2.58 0.6 10.1
13+ years (2) 20 18.5 0.30 2.40 0.5 11.3
No. of substances 3 substances (0) 42 38.9 0.25
2 substances (1) 31 28.7 0.09 2.66 0.9 8.4
1 substances (2) 35 32.4 0.43 1.60 0.5 5.1
Substance severitya Less severe (0) 62 57.4
More severe (1) 46 42.6 0.47 1.42 0.6 3.7
HSCL‑25b <1.75 (0) 19 17.6
1.75+ (1) 89 82.4 0.90 1.11 0.3 3.9
Temporary exit 2+ re‑entries (0) 19 17.6 0.67
1 re‑entry (1) 24 22.3 0.37 0.53 0.1 2.1
No exit (2) 65 60.2 0.58 0.70 0.2 2.5
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focused personal attention, to be a key element in partici-
pants’ retention in treatment [13, 43]. It is possible that 
the focused horse and human attention during HAT is a 
contributing factor to patients’ retention in treatment.
Depression, anxiety, aggression, poor motivation and 
low self-esteem are among the most commonly cited psy-
chological conditions associated with and responding to 
therapy with horses [16, 18, 21]. These conditions are also 
common elements of addiction comorbidity [54, 55]. The 
literature shows that distress scores on the HSCL-25 are 
very high at entry, because of the unstable condition at 
entry both emotionally (starting treatment) and because 
of the former drug use lifestyle. This may be one reason 
why we found no association between HSCL-25 and 
completion of treatment. Distress scores should be re-
examined in a broader study of HAT and comorbidity.
Given the naturalistic study design, we cannot infer 
causality. Nor should the results be interpreted as an 
assessment of HAT as a therapeutic process (for sub-
stance use or for other psychological disorders). The 
purpose of the study was simply to examine whether, as 
some patients claimed, participation in the HAT pro-
gram was associated with longer duration and comple-
tion of treatment. Further work is required to understand 
better HAT’s therapeutic processes, and the underlying 
causes of, and impact on comorbidity and longer-term 
treatment effect.
Strengths and limitations
The size and relative homogeneity of the population stud-
ied is a strength when compared with other studies of 
therapy involving horses. However, there are limitations 
to both internal and external validity. Nonrandom assign-
ment, including possible self-selection bias, is the most 
obvious limitation. The possible novelty effect of HAT 
is another. These shortcomings need to be addressed in 
large controlled studies that seek to clarify HAT’s role, 
including causal inference, in substance use disorder 
therapy, in treatment outcomes and treatment effect.
HAT participation was voluntary. Because there 
were no data on why patients joined or did not join the 
HAT program, it was not possible to form an opinion 
on whether the HAT participants stayed in treatment 
longer because they participated in the HAT program 
or because of some other positive factor, which also led 
them to participate in HAT. Data on patients’ motivation 
and program satisfaction (such as those used by Decker 
et al. [43]) might have been useful but were not available.
Dropout, the most frequently used measure of addic-
tion treatment outcome, is fraught with definitional 
and other problems [3, 4, 6, 10]. There is no consistent 
definition of the term. Many studies fail to define how 
they have used it and/or omit discussion of the impact 
of temporary exits. We did not find any studies that 
included dropout as a measure of treatment outcome for 
HAT, and therefore comparisons were not possible.
Our findings are consistent with claims that HAT has 
a positive effect on psychosocial illness. However, we 
acknowledge this could be due, in whole or in part, to 
a variety of possible confounding factors that were not 
examined (such as, for example the “honeymoon” effect 
of a new program, the outdoor environment or the ambi-
ence around the stables). These factors lend themselves 
initially to qualitative investigation.
It is possible that a similar effect might be obtained 
more economically with another animal, such as a dog. 
Inclusion of dogs in substance misuse therapy has been 
found to improve therapeutic relationships [56]. How-
ever, we have found no studies which compare the use 
of horses with other animals as an adjunct therapy for 
substance misuse but note that Nurenberg [32] and 
colleagues in their comparison did find a significantly 
positive effect of therapy involving horses, but not dogs, 
when incorporated into psychotherapy for aggressive 
behavior.
Relevance
Ongoing care was not addressed in the study. However, 
HAT may have considerable potential as a community-
based activity for outpatient treatment. If available from 
accredited public and private providers in community 
settings, it may enable engagement in healthy, pleasur-
able outdoor activities with a nonsubstance use peer 
group.
There is a continuous struggle to find what motivates 
substance use disorder patients to remain healthy. Rig-
orous evidence of safety and efficacy is required before 
HAT can become a conventionally accepted treatment 
with the associated provision of health insurance cover 
[57–59]. The positive findings from this treatment facil-
ity-based study, and HAT’s broader community potential, 
prompt further investigation of both the underlying ther-
apeutic processes and the longer-term impact of HAT on 
substance use disorder treatment.
Conclusion
This naturalistic study used intention-to-treat analysis 
to examine HAT in a substance use disorder treatment 
program for young adults. The objective was to assess 
whether HAT patients remained in treatment longer and 
were more likely to complete their agreed program of 
treatment than were non-HAT patients. It found statisti-
cally significant associations between HAT participation 
and duration and completion of treatment. These find-
ings are consistent with the claims of patients and the 
growing body of equine therapy literature. However, the 
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study does not indicate whether either HAT or the horses 
per se might have accounted for the results. Investment is 
needed in larger controlled studies, in qualitative investi-
gation of the patients’ and clinicians’ perspectives, and in 
the ethological study of the horses’ actual contribution in 
the therapeutic process.
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